Enliven Therapeutics, Inc. Common Stock (ELVN) is a publicly traded Healthcare sector company. As of May 20, 2026, ELVN trades at $41.87 with a market cap of $2.41B and a P/E ratio of -22.91. ELVN moved +4.27% today. Year to date, ELVN is +175.21%; over the trailing twelve months it is +140.85%. Its 52-week range spans $13.30 to $48.53. Analyst consensus is strong buy with an average price target of $57.14. Rallies surfaces ELVN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for ELVN combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $41.87 |
| Market Cap | $2.41B |
| P/E Ratio | -22.91 |
| EPS | $-1.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $48.53 |
| 52-Week Low | $13.30 |
| Volume | 567.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-103.69M |
| Gross Margin | 0.00% |
8 analysts cover ELVN: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $57.14.